Drugs / PK1
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00003165 | Dec 1997 → ? | breast cancer | University of Glasgow | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PK1 | “A Phase II Trial of PK1 in Women With Advanced Breast Cancer” NCT00003165 ↗ |
| Known as | doxorubicin-HPMA conjugate | “Patients receive doxorubicin-HPMA conjugate (PK1) by intravenous infusion once every 3 weeks.” NCT00003165 ↗ |
| Route | Intravenous | “by intravenous infusion” NCT00003165 ↗ |